5d
Stockhead on MSNDr Boreham’s Crucible: What’s all the fuss about biotech behemoth CSL?If newly appointed US health secretary and anti-vaxxer Robert F Kennedy Junior really wants vaccination rates to fall, he won ...
Hosted on MSN16d
Haemonetics targets 24% to 26% hospital revenue growth with momentum in hemostasis and vascular closureCEO Christopher Simon reported third ... led by innovations in hemostasis management and vascular closure. While plasma revenue faced headwinds from CSL's transition, the company continued to ...
Australian biopharmaceutical company CSL reported a drop in vaccine sales due to falling immunization rates in the U.S., its largest market. The decline contributed to lower-than-expected profits, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results